E068 Achievement of low disease activity over 52 weeks in patients with active axial spondyloarthritis on bimekizumab treatment: results from the phase 3 studies BE MOBILE 1 and BE MOBILE 2

Xenofon Baraliakos,Sofia Ramiro,Marina Magrey,Martin Rudwaleit,Nigil Haroon,Carmen Fleurinck,Ute Massow,Natasha de Peyrecave,Thomas Vaux,Helena Marzo-Ortega,Victoria Navarro-Compán

DOI: https://doi.org/10.1093/rheumatology/keae163.295

2024-04-01

Rheumatology

Abstract:Abstract Background/Aims The recommended treatment target for axial spondyloarthritis (axSpA) is remission/low disease activity (LDA) according to Ankylosing Spondylitis Disease Activity Score (ASDAS) levels (ASDAS<2.1); however, remission is difficult to achieve for many patients. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) remains commonly used in clinical practice to assess disease activity, although limited data exist to validate cut-offs. Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. BKZ has demonstrated consistent and sustained efficacy up to Week (Wk)52 in the BE MOBILE 1 and 2 phase 3 studies, including achievement of LDA according to ASDAS by > 50% of patients with non-radiographic (nr-)axSpA and radiographic (r-)axSpA. Here, we report achievement of LDA, as assessed by either ASDAS<2.1, BASDAI<4, or both, to Wk52 with BKZ across the spectrum of axSpA in two phase 3 studies. Methods BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) comprised a 16-wk placebo (PBO)-controlled and 36-wk maintenance period. BE MOBILE 1 (nr-axSpA) patients met Assessment of SpondyloArthritis international Society (ASAS) classification criteria and had objective inflammation (MRI and/or elevated C-reactive protein). BE MOBILE 2 (r-axSpA) patients met modified New York and ASAS classification criteria. All patients had active disease (BASDAI≥4 and spinal pain≥4 [BASDAI item 2]) at baseline. Patients were randomised to subcutaneous BKZ 160 mg every 4 weeks (Q4W) or PBO. Patients randomised to PBO switched to BKZ from Wk16 (‘PBO/BKZ-switchers’). The proportion of patients that achieved LDA to Wk52, as defined by either ASDAS<2.1, BASDAI<4, or both, are presented (non-responder imputation). Results Overall, 254 patients with nr-axSpA (BKZ: 128/PBO: 126) and 332 with r-axSpA (BKZ: 221/PBO: 111) were randomised. Most had high (ASDAS≥2.1-≤3.5) or very high (ASDAS>3.5) disease activity at baseline (nr-axSpA: BKZ: 99.2%/PBO: 97.6%; r-axSpA: BKZ: 98.6%/PBO: 100%). At Wk16, a greater proportion of BKZ vs PBO-treated patients achieved ASDAS<2.1 (nr-axSpA: BKZ: 46.1%/PBO: 19.8%; r-axSpA: BKZ: 42.1%/PBO: 17.1%), BASDAI<4 (nr-axSpA: BKZ: 52.3%/PBO: 31.7%; r-axSpA: BKZ: 55.7%/PBO: 41.4%) and both (nr-axSpA: BKZ: 43.8%/PBO: 19.0%; r-axSpA: BKZ: 41.6%/PBO: 17.1%). Results were sustained/improved across continuous BKZ-treated patients and PBO/BKZ-switchers to Wk52, with achievement of ASDAS<2.1 (nr-axSpA: BKZ: 53.9%/switchers: 47.6%; r-axSpA: BKZ: 50.2%/switchers: 61.3%), BASDAI<4 (nr-axSpA: BKZ: 60.2%/switchers: 54.0%; r-axSpA: BKZ: 65.6%/switchers: 68.5%) and both (nr-axSpA: BKZ: 49.2%/switchers: 45.2%; r-axSpA: BKZ: 49.8%/switchers: 58.6%). Achievement of BASDAI<4 was consistently higher than ASDAS<2.1, regardless of treatment arm. Conclusion Across the full axSpA disease spectrum, BKZ resulted in rapid achievement of LDA vs PBO to Wk16, as assessed by ASDAS<2.1, BASDAI<4, or both; improvements continued to Wk52. Most patients achieving ASDAS<2.1 also achieved BASDAI<4. These data suggest ASDAS<2.1 is a more stringent criterion for LDA, relevant for consideration of BKZ in the context of a potential treat-to-target approach for axSpA in daily practice. Disclosure X. Baraliakos: Consultancies; AbbVie, BMS, Chugai, Eli Lilly, Galapagos, Gilead, Novartis, Pfizer and UCB Pharma ; grant/research support from: Novartis and UCB Pharma. Member of speakers’ bureau; AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma. Other; Paid instructor for: AbbVie, BMS, Chugai, Eli Lilly, Galapagos, MSD, Novartis, Pfizer and UCB Pharma. S. Ramiro: Grants/research support; AbbVie, Galapagos, MSD, Novartis, Pfizer and UCB Pharma; Consultant for AbbVie, Eli Lilly, Novartis, Pfizer, Sanofi and UCB Pharma. M. Magrey: Consultancies; AbbVie, BMS, Eli Lilly, Novartis, Pfizer and UCB Pharma. Grants/research support; AbbVie, BMS and UCB Pharma. M. Rudwaleit: Consultancies; AbbVie, Eli Lilly, Novartis and UCB Pharma. Member of speakers’ bureau; AbbVie, Boehringer Ingelheim, Chugai, Eli Lilly, Janssen, Novartis, Pfizer and UCB Pharma. N. Haroon: Consultancies; AbbVie, Eli Lilly, Janssen, Novartis and UCB Pharma. C. Fleurinck: Other; Employees of UCB Pharma. U. Massow: Other; Employees of UCB Pharma. N. de Peyrecave: Other; Employees of UCB Pharma. T. Vaux: Other; Employees of UCB Pharma. H. Marzo-Ortega: Consultancies; AbbVie, Biogen, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB Pharma. Honoraria; AbbVie, Biogen, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda and UCB Pharma. Grants/research support; Janssen, Novartis and UCB Pharma. V. Navarro-Compán: Consultancies; AbbVie, Eli Lilly, Galapagos, MoonLake, MSD, Novartis, Pfizer and UCB Pharma. Member of speakers’ bureau; AbbVie, Eli Lilly, Fresenius Kabi, Janssen, MSD, Novartis, Pfizer and UCB Pharma. Grants/research support; AbbVie and Novartis.

rheumatology

What problem does this paper attempt to address?

This paper aims to explore the long - term efficacy maintenance of Bimekizumab (BKZ) in treating psoriatic arthritis (PsA) patients who have an insufficient response or are intolerant to tumor necrosis factor inhibitors (TNF inhibitors, TNFi). Specifically, the study focuses on whether patients who respond to BKZ treatment at week 16 can continuously maintain the improvement of joint, skin and composite efficacy indicators at week 52.

### Research Background and Objectives

Psoriatic arthritis is a chronic disease that affects multiple areas, but patients may lose their response to treatment during long - term treatment. Therefore, maintaining long - term treatment effects is crucial for these patients. Bimekizumab (BKZ) is a monoclonal IgG1 antibody that can selectively inhibit interleukin - 17F (IL - 17F) and IL - 17A, showing rapid and clinically significant improvement in joint and skin efficacy. The purpose of this study is to report the efficacy maintenance of PsA patients treated with BKZ from week 16 when they reach a response to week 52.

### Main Research Methods

The study design includes a 16 - week double - blind period and an open - label extension period. During the 16 - week double - blind period, patients were randomly assigned to receive BKZ 160 mg every 4 weeks (Q4W) or placebo (PBO). Patients who completed 16 - week treatment could enter the open - label extension period. The primary endpoint of the study was the proportion of patients who responded at week 16 and continued to maintain the response in the BKZ treatment group at week 52.

### Main Research Results

- **Overall Response Rate**: At week 16, 67.0% of patients in the BKZ treatment group achieved ACR20 response, 43.4% achieved ACR50 response, and 26.6% achieved ACR70 response. These responses were well maintained at week 52, with 81.6%, 80.2% and 83.1% of patients continuing to maintain the response respectively.
- **Skin Symptom Improvement**: Among 176 patients with more than 3% skin involvement area at baseline, 82.4% achieved PASI75 response at week 16, 68.8% achieved PASI90 response, and 58.5% achieved PASI100 response. These responses were also well maintained at week 52, with 88.3%, 88.4% and 84.5% of patients continuing to maintain the response respectively.
- **Low Disease Activity (MDA) and Very Low Disease Activity (VLDA)**: At week 16, 44.2% of patients achieved MDA, and 81.4% of these patients continued to maintain MDA at week 52. Similarly, patients who achieved VLDA and DAPSA REM + LDA at week 16 also had a high proportion of maintaining the response at week 52.

### Safety

As of week 52, 62.6% of 388 patients receiving BKZ treatment reported at least 1 treatment - related adverse event (TEAE), and 5.9% reported serious adverse events (serious TEAEs).

### Conclusion

Bimekizumab shows strong efficacy maintenance ability in psoriatic arthritis patients who have an insufficient response or are intolerant to TNF inhibitors. From week 16 to week 52, most patients' joint, skin and composite efficacy indicators have been continuously improved. In terms of safety, the safety profile of BKZ is consistent with previous reports.